Patient Files: Crohn's disease
Carly Medosch on the difficulties of getting people to understand the inflammatory bowel disease
PharmaTimes -
December 2016
Compared to other world events, pharma's 2016 has been relatively calm - but that doesn't mean that this year hasn't brought significant changes for the industry.
In our Review of 2016 (p23), we round up all the most important issues of the year for the industry and add some expert analysis to help you prepare for 2017. Political upheaval, innovation in the NHS, the growth of biosimilars and big changes to market access have all forced pharma to rethink its strategy for the next few years - but as the industry's position on these solidifies we can at least say that it should be be tackling them from a position of strength.
After all, these issues are only going to continue into 2017 - as shown by our SmartViews pieces on the NHS' drive to improve mental health services (Thinking alike, p17) and NICE's new rules (A new way in, p20), as well as our feature on the downsides of minimising drug prices (The bigger picture, p38).
December 2016 - magazine highlights
Thinking alike
How can pharma help the NHS achieve Parity of Esteem in mental health?
Difficult breathing
Mesothelioma expert Dr Raja Flores on the state of treatment for this often neglected disease
A new way in
The ins and out of the controversial proposed changes to NICE and its HST assessments
The bigger picture
Delivering the maximum possible benefits to the NHS does not necessarily mean minimising prices, finds a new report
Review of the year 2016: Digital
The biggest digital developments of 2016
Review of the year 2016: Five Year Forward View
How the NHS moved forward in 2016
Review of the year 2016: Brexit
Pharma expects a Brexit hit in 2017 and beyond
Review of the year 2016: Biosimilars
The copycat drugs have remained controversial in 2016, but it has also been their most successful year yet
Review of the year 2016: M&A
Merger mania slowed but certainly didn't disappear in 2016
Review of the year 2016: Market access
NHS made big strides in market access this year with the Accelerated Access Review and changes to the CDF – but will they work?
Trump and Brexit: Good news for pharma?
The industry needs to tread carefully in the future – but there could be upsides to having less red tape and softer tax policies
